WebDoctor Encyclopedia

Head & neck Lung

NUT carcinoma

NUT carcinoma is a rare, very aggressive cancer caused by a NUTM1 gene fusion. It grows in the head and neck or chest, often in young people, is not linked with smoking and is treated with surgery, radiotherapy and chemotherapy.

Medically reviewed Last reviewed October 27, 2026

What is NUT carcinoma?

NUT carcinoma is a rare and very aggressive cancer defined by a specific gene change involving the NUTM1 gene. It was formerly called NUT midline carcinoma, because it usually grows in structures along the middle of the body.

The most common sites are the head and neck, especially the nose and sinuses, and the chest, including the lungs and mediastinum (the space between the lungs).

NUT carcinoma can occur at any age, but it affects children, teenagers and young adults more often than most carcinomas. Unlike many head and neck or lung cancers, it is not linked with smoking, alcohol or HPV.

NUT carcinoma grows quickly and is often diagnosed at an advanced stage. Its outlook is poor, but some people, particularly those whose tumour can be completely removed, do much better (Chau et al., 2016).

Because NUT carcinoma looks like other poorly differentiated cancers under the microscope, it is probably under-diagnosed. Some cases are first reported as squamous cell carcinoma, undifferentiated carcinoma or even a small round cell sarcoma. Experts recommend that pathologists test for it more widely (Luo et al., 2025).

1. Key facts at a glance

Feature Details
Type of cancer Poorly differentiated carcinoma with squamous features
Defining change NUTM1 gene rearrangement (most often BRD4::NUTM1)
How common Rare, but probably under-recognised
Typical age Any age; median about 20-30
Main sites Head and neck (nose, sinuses, salivary glands, larynx) and chest (lung, mediastinum)
Main test NUT protein staining on the biopsy
Main treatment Surgery, radiotherapy and chemotherapy; clinical trials
Outlook Median survival under a year in most series; better after complete surgery

2. How NUT carcinoma develops

The NUTM1 gene is normally active only in the testis. In NUT carcinoma, a chromosome break joins NUTM1 to another gene, creating a fusion gene (French et al., 2014; French et al., 2022).

The fusion protein holds the cell in an immature, rapidly dividing state, mainly by switching on growth genes such as MYC.

Fusion Approximate share Notes
BRD4::NUTM1 About 70-75% Most common; often the most aggressive
BRD3::NUTM1 About 15% May have a slightly better outlook
NSD3::NUTM1 About 5-10% May have a slightly better outlook
Other partners A few per cent Rare

Causes and risk factors

The cause of the fusion is not known. It is not inherited and is not linked with lifestyle factors.

Factor Known link?
Smoking No
Alcohol No
HPV or Epstein-Barr virus No
Family history No
Age Can occur from infancy to old age

3. How does it look

Under the microscope

NUT carcinoma consists of sheets of small to medium-sized, uniform, undifferentiated cells. Many tumours show abrupt keratinisation: sudden islands of mature squamous cells among the immature cells.

The key test is immunohistochemistry for NUT protein. More than half of the tumour cell nuclei show a speckled brown staining pattern, and this finding is diagnostic.

The fusion can also be confirmed with FISH or RNA sequencing.

Look-alike tumour How NUT carcinoma differs
Poorly differentiated squamous cell carcinoma Positive NUT stain; younger patients; no smoking or HPV link
Sinonasal undifferentiated carcinoma Positive NUT stain
Ewing sarcoma and other small round cell tumours Positive NUT stain and keratin
Lymphoma Keratin-positive, lymphoid markers negative
Germ cell tumour Different markers; NUT stain positive

The tumour itself

NUT carcinoma usually forms a large, fast-growing mass that invades nearby structures. Areas of dead tissue (necrosis) are common.

On scans

Site Typical findings
Nose and sinuses A mass destroying bone, sometimes growing into the eye socket or skull base
Lung A large central mass, often with enlarged lymph nodes and fluid around the lung
Mediastinum A mass in the middle of the chest pressing on airways or blood vessels
Spread Bones, lymph nodes, lungs, liver and pleura, best shown by PET-CT

Visible signs

Sign What it looks like
Facial swelling Over the cheek, around the eye or near the nose
Bulging or displaced eye From a sinus tumour growing into the eye socket
Neck lump An enlarged lymph node or a tumour of the thyroid or salivary gland
Swollen face and neck veins From a chest tumour pressing on the large vein to the heart (superior vena cava obstruction)
Weight loss In advanced disease

4. Symptoms

Symptoms depend on where the cancer starts. Because the tumour grows quickly, symptoms often worsen over weeks.

Head and neck

  • Blocked nose, usually on one side
  • Nosebleeds
  • Facial pain, swelling or numbness
  • Bulging eye, double vision or watery eye
  • Headache
  • Neck lump
  • Hoarse voice or difficulty swallowing, for tumours of the larynx or throat

Chest

  • Persistent cough, sometimes with blood
  • Chest pain
  • Shortness of breath
  • Swelling of the face, neck and arms if the tumour presses on the superior vena cava
  • Fever, night sweats and weight loss

Spread to other areas

  • Bone pain, especially in the back
  • Tiredness and loss of appetite

When to seek medical advice

See a doctor promptly if you have a one-sided blocked nose with bleeding, facial swelling, a neck lump or a cough that does not go away, especially if symptoms are getting worse.

Seek urgent help for breathlessness, swelling of the face and neck, or coughing up blood.

5. Diagnosis

Test Purpose
Biopsy Essential; ideally a generous tissue sample
NUT immunohistochemistry Diagnostic when strongly positive
FISH or RNA sequencing Confirms NUTM1 rearrangement and identifies the fusion partner
CT and MRI of the primary site Show the size and local extent
PET-CT Checks for spread throughout the body
MRI of the brain If symptoms suggest spread
Endoscopy or bronchoscopy To examine and sample the nose, throat or airways

NUT carcinoma is staged using the same system as other cancers at the same site, for example head and neck or lung staging.

6. Treatment

NUT carcinoma should be treated at a specialist cancer centre with experience of rare tumours. Many experts recommend starting treatment quickly, because the cancer can progress within weeks.

International groups have published guidance on diagnosis and treatment (Zhang et al., 2026).

Surgery

Complete surgical removal with clear margins is linked with the best outcomes, particularly for head and neck tumours (Chau et al., 2016; Giridhar et al., 2018). Surgery may be done at the start or after chemotherapy has shrunk the tumour.

Radiotherapy

High-dose radiotherapy to the tumour area is usually given after surgery or as the main local treatment when surgery is not possible. It is often combined with chemotherapy.

Chemotherapy

Approach Details
Sarcoma-type regimens Ifosfamide-based combinations, sometimes used as in Ewing sarcoma
Platinum-based regimens Cisplatin or carboplatin with other drugs, as used in squamous cell carcinoma
Taxanes Often added in combination

Responses to chemotherapy are often short-lived, so it is usually combined with surgery and radiotherapy.

Newer treatments

Treatment Status
BET inhibitors Target the BRD4 part of the fusion; some responses in trials, though side effects and short responses are a problem (Stathis and Bertoni, 2018)
Combinations with BET inhibitors Being tested with chemotherapy and other targeted drugs
CDK9 and p300 inhibitors Early research
Immunotherapy Being studied; occasional responses reported
Clinical trials Strongly recommended

Why treatment is combined

No single treatment controls NUT carcinoma reliably on its own. Most specialists therefore plan all three treatments together from the start: chemotherapy to shrink the tumour and treat hidden spread, surgery to remove the tumour completely where possible, and radiotherapy to reduce the risk of the cancer returning in the same place.

The exact order depends on the site and size of the tumour. For example, a small sinus tumour may be removed first, while a large chest tumour may be treated with chemotherapy first.

Supportive care

Problem Support
Pain Pain specialists and palliative care teams
Breathing problems Stents, drainage of fluid or radiotherapy
Eating and swallowing Dietitians and speech therapists
Emotional impact Psychologists and support groups, especially for young people

Early involvement of a palliative care team helps control symptoms. It can be offered alongside active treatment from the start.

7. Outlook (prognosis)

NUT carcinoma has a poor outlook overall. In large series, the median survival is about 6-10 months (Bauer et al., 2012; Chau et al., 2020).

Some patients, however, survive for many years, particularly when the tumour is found early and removed completely.

Factor Effect
Head and neck site Better outlook than chest tumours
Non-BRD4 fusion (BRD3 or NSD3) Better outlook in some studies
Complete surgical removal Strongest link with long-term survival
Chest primary or spread at diagnosis Poorer outlook
Rapid start of combined treatment May improve outcomes

A prognostic model based on the site of the tumour and the fusion type can help doctors estimate outlook (Chau et al., 2020).

NUT carcinoma in children and teenagers

NUT carcinoma is one of the few carcinomas that occurs regularly in children and adolescents. Young patients are usually treated by paediatric or teenage and young adult cancer teams, working with head and neck or thoracic specialists.

Treatment is often based on intensive regimens used for sarcomas, together with surgery and radiotherapy. Families are offered the same support services as for other childhood cancers.

Follow-up after treatment

Time after treatment Typical follow-up
First 2 years Clinic visits and scans every 2-3 months, as most relapses happen early
Years 3-5 Visits and scans every 3-6 months
After 5 years Yearly review, including late effects of radiotherapy and chemotherapy

Late effects can include dry mouth, swallowing difficulties, hormone changes after head and neck radiotherapy, and lung or heart effects after chest treatment.

Registries and research

Because NUT carcinoma is rare, every patient adds valuable knowledge. An international NUT carcinoma registry collects information and tissue to improve understanding and treatment. Your team can explain how to take part.

8. Living with NUT carcinoma

  • Ask for a second opinion at a centre familiar with NUT carcinoma
  • Ask about trials and the international NUT carcinoma registry
  • Plan treatment quickly, because delays matter
  • Look after nutrition, especially during head and neck radiotherapy
  • Seek emotional support for yourself and your family
  • Keep copies of your pathology report, including the fusion type, to share with other doctors

9. Frequently asked questions

Question Answer
Is NUT carcinoma related to smoking? No
Why is it called NUT? NUT stands for “nuclear protein in testis”, the normal role of the NUTM1 gene
Is it inherited? No
Why was my cancer first called something else? It can look like other undifferentiated cancers until the NUT stain is done
Can it be cured? Long-term survival is possible, mainly after complete surgery with radiotherapy
Can children get NUT carcinoma? Yes. It is one of the few carcinomas seen regularly in children and teenagers
Should my tumour be retested? If you were diagnosed with an undifferentiated or squamous cancer at a young age without smoking, ask whether NUT testing was done
How quickly should treatment start? As soon as possible, ideally within days to a few weeks of diagnosis

10. Questions to ask your care team

  • Has the diagnosis been confirmed by NUT staining or genetic testing?
  • Which fusion partner does my tumour have?
  • Can the tumour be completely removed?
  • What combination of surgery, radiotherapy and chemotherapy do you recommend?
  • Are there clinical trials I can join?
  • Who can help with symptoms and support?

Resources

  1. French, C.A. et al. (2014) ‘NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism’, Cancer Discovery, 4(8), pp. 928-941.
  2. French, C.A. et al. (2022) ‘Report of the first international symposium on NUT carcinoma’, Clinical Cancer Research, 28(12), pp. 2493-2505.
  3. Bauer, D.E. et al. (2012) ‘Clinicopathologic features and long-term outcomes of NUT midline carcinoma’, Clinical Cancer Research, 18(20), pp. 5773-5779.
  4. Chau, N.G. et al. (2016) ‘Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck’, Cancer, 122(23), pp. 3632-3640.
  5. Chau, N.G. et al. (2020) ‘An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: analysis of 124 patients’, JNCI Cancer Spectrum, 4(2), p. pkz094.
  6. Giridhar, P. et al. (2018) ‘Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases’, European Archives of Oto-Rhino-Laryngology, 275(3), pp. 815-821.
  7. Stathis, A. and Bertoni, F. (2018) ‘BET proteins as targets for anticancer treatment’, Cancer Discovery, 8(1), pp. 24-36.
  8. Luo, J. et al. (2025) ‘Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck’, Nature Reviews Clinical Oncology, 22(4), pp. 292-306.
  9. Zhang, Y. et al. (2026) ‘International guidelines on the diagnosis and treatment of NUT carcinoma’, The Innovation, 7(1), p. 101068.

Prepared by the editorial team, October 2026.